Provides broad overview of Company's research and early development programs expected to continue to fuel future growth Highlights ... · ACCESS Newswire · Moderna, Inc. The above button links to ...
The Moderna Innovation and Technology Centre (MITC) at Harwell Science and Innovation Campus. Moderna and the University of Oxford in the UK have been cleared to start human trials of what could be ...
As it prepares to launch up to three new products from 2027 through 2028, Moderna is adjusting its way of doing business. The company has hired Ester Banque as its chief commercial officer and has ...
An FDA panel voted 9-0 that the benefits of Moderna’s mRNA-1010 flu vaccine outweigh risks for adults aged 50 and older.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
FDA's advisory committee will vote on June 18 whether mFlusiva benefits outweigh risks in older adults Moderna seeks accelerated approval of mFlusiva for adults 65 and older If approved, mFlusiva will ...
June 16 (Reuters) - Staff of the U.S. Food and Drug Administration said on Tuesday that data demonstrating a strong immune response to Moderna's flu shot may support effectiveness in adults 65 years ...
From mainframes, to Mac OS, and everything in between. From mainframes, to Mac OS, and everything in between. is the Verge’s weekend editor. He’s covered the tech industry for over 18 years and knows ...
Moderna (MRNA) shares reached the highest level since March after the FDA issued comments that Jefferies said gave a “balanced” view on the company’s flu vaccine candidate, mRNA-1010, ahead of an ...
Morning Overview on MSN
A Moderna mRNA flu shot won a unanimous FDA panel nod for older adults
Older adults who face the highest rates of flu hospitalization moved one step closer to a new vaccine option on June 18, 2026 ...
Moderna is restructuring its organization and leadership in preparation for a new wave of product launches, expanding President Stephen Hoge's role and appointing longtime pharma executive Ester ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results